Welcome to our dedicated page for Cyclerion Therapeutics SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cyclerion Therapeutics, Inc. (CYCN), a Nasdaq-listed clinical-stage biopharmaceutical company focused on neuropsychiatric diseases and treatment-resistant depression. These regulatory documents offer detailed insight into Cyclerion’s material agreements, strategy shifts, governance, and capital structure.
Among the key filings are current reports on Form 8-K that describe significant corporate events. For example, Cyclerion has filed an 8-K outlining a patent license agreement with the Massachusetts Institute of Technology, under which MIT granted the company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. The filing explains milestone payment obligations, royalty ranges, sublicensing economics, and responsibilities for patent prosecution and maintenance.
Other 8-K filings detail shareholder meeting results, including the election of directors, advisory votes on executive compensation, and auditor ratification. These documents also record actions such as reverse stock splits and provide information on Nasdaq listing matters. Together with annual and quarterly reports, these filings help investors understand Cyclerion’s evolution from an sGC-focused company to a neuropsychiatric-focused organization and its approach to monetizing legacy assets through sales, licenses, and option agreements.
On Stock Titan, Cyclerion’s SEC filings are updated as they are posted to the EDGAR system. AI-powered tools summarize lengthy documents, highlight key terms in agreements, and surface items such as milestone structures, royalty provisions, and board or shareholder decisions. Users can also review insider and governance-related disclosures where applicable, using these structured summaries to navigate complex regulatory texts more efficiently.